CA2952968A1 - Derives d'acide boronique et leurs utilisations therapeutiques - Google Patents

Derives d'acide boronique et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2952968A1
CA2952968A1 CA2952968A CA2952968A CA2952968A1 CA 2952968 A1 CA2952968 A1 CA 2952968A1 CA 2952968 A CA2952968 A CA 2952968A CA 2952968 A CA2952968 A CA 2952968A CA 2952968 A1 CA2952968 A1 CA 2952968A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
nr1r2
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2952968A
Other languages
English (en)
Inventor
Raja K. Reddy
Tomasz Glinka
Maxim Totrov
Scott Hecker
Olga Rodny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rempex Pharmaceuticals Inc
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of CA2952968A1 publication Critical patent/CA2952968A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2952968A 2014-07-01 2015-06-29 Derives d'acide boronique et leurs utilisations therapeutiques Abandoned CA2952968A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019758P 2014-07-01 2014-07-01
US62/019,758 2014-07-01
PCT/US2015/038364 WO2016003929A1 (fr) 2014-07-01 2015-06-29 Dérivés d'acide boronique et leurs utilisations thérapeutiques

Publications (1)

Publication Number Publication Date
CA2952968A1 true CA2952968A1 (fr) 2016-01-07

Family

ID=55019887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952968A Abandoned CA2952968A1 (fr) 2014-07-01 2015-06-29 Derives d'acide boronique et leurs utilisations therapeutiques

Country Status (11)

Country Link
US (1) US10206937B2 (fr)
EP (1) EP3164406B1 (fr)
JP (1) JP6700203B2 (fr)
KR (1) KR20170024087A (fr)
CN (1) CN106536529B (fr)
AU (1) AU2015284307A1 (fr)
CA (1) CA2952968A1 (fr)
EA (1) EA201692301A1 (fr)
MX (1) MX2016016666A (fr)
WO (1) WO2016003929A1 (fr)
ZA (1) ZA201608682B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
EP2941246A4 (fr) 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc Dérivés d'acide boronique et leurs utilisations thérapeutiques
ES2730013T3 (es) * 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3140310B1 (fr) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthèse de sels boronate et utilisations de ceux-ci
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016081297A1 (fr) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Dérivés d'esters d'acide boronique cycliques et leurs utilisations thérapeutiques
US20180051041A1 (en) * 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
CN106008446A (zh) * 2016-04-29 2016-10-12 广州药本君安医药科技股份有限公司 呫吨酮衍生物及呫吨酮和其衍生物的制备方法与用途
MY196909A (en) * 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
WO2018199291A1 (fr) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 Dérivé hétérocyclique
EP3630782A4 (fr) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéines de liaison à la pénicilline
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
TW201906616A (zh) * 2017-07-06 2019-02-16 日商大日本住友製藥股份有限公司 醯胺衍生物
WO2019009369A1 (fr) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 Dérivé d'imine
EP3694864B1 (fr) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Dérivés d'acide boronique et synthèse de ces derniers
AU2019256351B2 (en) * 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN118638140A (zh) 2018-04-27 2024-09-13 住友制药株式会社 氧代取代化合物
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
EP3886798B1 (fr) 2018-11-29 2026-01-28 Venatorx Pharmaceuticals, Inc. Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
WO2021079984A1 (fr) 2019-10-25 2021-04-29 大日本住友製薬株式会社 Nouveau composé cyclique condensé substitué
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
CN110938015B (zh) * 2019-12-06 2022-10-25 重庆工商大学 一种叠氮基取代的水杨酸衍生物的制备方法
US12552815B2 (en) 2020-05-05 2026-02-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN113150022B (zh) * 2021-04-23 2022-12-06 四川大学 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
CN117343088A (zh) * 2022-07-05 2024-01-05 福安药业集团重庆三禾兴医药科技有限公司 一类7-((五元杂环)甲基)-8-羧酸-苯并环硼酸酯类衍生物及其用途
US20250099495A1 (en) * 2023-09-22 2025-03-27 City University Of Hong Kong Methods of inhibiting klebsiella pneumoniae carbapenemase-2
WO2025119216A1 (fr) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 INHIBITEUR DE β-LACTAMASE D'ACIDE BORONIQUE, PROCÉDÉ DE PRÉPARATION ASSOCIÉ ET UTILISATION ASSOCIÉE

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) * 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4758557A (en) 1985-06-26 1988-07-19 Meiji Seika Kaisha, Ltd. Cephalosporin derivatives and bactericides containing the same
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CA1283404C (fr) 1986-07-01 1991-04-23 Shigeru Sanai Composes de cephalosporine, procede de preparation et agents antibacteriens
US5028601A (en) 1987-04-30 1991-07-02 Meiji Saika Kaisha, Ltd. Cephalosporin compounds and antibacterial agents
EP0333082A3 (fr) 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Composés céphem, leur préparation et application
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6075014A (en) 1997-06-13 2000-06-13 Northwestern University Inhibitors of β-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO2000035905A1 (fr) 1998-12-16 2000-06-22 Northwestern University INHIBITEURS DE β-LACTAMASES ET LEUR UTILISATION
WO2000035904A1 (fr) 1998-12-16 2000-06-22 Northwestern University INHIBITEURS DE β-LACTAMASES ET LEUR UTILISATION
KR20010101355A (ko) 1999-01-02 2001-11-14 로버트 흐라이탁, 미쉘 베스트 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 xa 활성 억제)
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
AU762935B2 (en) 1999-10-28 2003-07-10 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
WO2002022613A1 (fr) 2000-09-14 2002-03-21 Pantherix Limited Derives d'acides 3-(heteroaryl-acetamido)-2-oxo-azetidine-1-sulfoniques, utilises comme agents antibacteriens
WO2002054931A2 (fr) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Acides alpha-aminoboroniques prepares par de nouvelles methodes de synthese
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
AU2003268752A1 (en) 2002-10-30 2004-05-25 Sumitomo Chemical Company, Limited High-molecular compounds and polymerer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ(ant)リガンドならびにそれに関連する組成物および方法
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
WO2004084898A1 (fr) 2003-03-24 2004-10-07 Actimis Pharmaceuticals, Inc. Derives de 2-phenoxy- et 2-phenylsulfonamide a activite antagoniste de ccr3 pour le traitement de l'asthme et d'autres troubles inflammatoires ou immunologiques
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
WO2005020975A2 (fr) 2003-08-27 2005-03-10 Eli Lilly And Company Traitement de difficultes d'apprentissage et de troubles de la motricite faisant appel a des inhibiteurs de la recapture de la noradrenaline
JP2005089383A (ja) 2003-09-18 2005-04-07 Bayer Cropscience Ag 新規チアジアゾール含有ジフルオロアルケン類及び有害生物防除剤としての利用
WO2005033090A1 (fr) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited Compose aromatique
EP1678180B1 (fr) 2003-10-10 2007-08-08 Pfizer Products Incorporated 2h-[1,2,4|triazolo 4,3-a|pyrazines substituees en tant qu'inhibiteurs de la gsk-3
EP1689757B1 (fr) 2003-11-12 2014-08-27 Phenomix Corporation Composes heterocycliques d'acide boronique
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ,インコーポレイテッド ホウ素含有小分子
CA2683975A1 (fr) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Rosuvastatine, sels de rosuvastatine exempts de son alkylether, procede d'elaboration correspondant
WO2006101779A2 (fr) 2005-03-15 2006-09-28 The University Of Chicago Electrolytes non aqueux destines a des batteries au lithium-ion
KR100648133B1 (ko) 2005-04-25 2006-11-23 일동제약주식회사 펩티드 데포르밀라제 저해제로서 신규의 히드록사믹 산유도체 및 그 제조방법
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
ATE529111T1 (de) 2005-12-07 2011-11-15 Basilea Pharmaceutica Ag Nützliche monobactam-antibiotika
NZ570257A (en) 2006-02-16 2011-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
WO2008039420A2 (fr) 2006-09-27 2008-04-03 Merck & Co., Inc. Nouveaux inhibiteurs de bêta-lactamase
KR101320718B1 (ko) 2007-03-23 2013-10-21 바실리어 파마슈티카 아게 세균 감염 치료용 조합 약제
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CN101983203A (zh) 2007-11-13 2011-03-02 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
MY162532A (en) 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009134850A1 (fr) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Inhibiteurs de la prolylhydroxylase
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110124634A1 (en) 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
WO2010030811A2 (fr) 2008-09-10 2010-03-18 Achaogen, Inc. Antibiotiques de type β-lactame à base de carbacéphème
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (fr) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. Procédé de préparation amélioré pour le cefpodoxime proxétil
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
KR20130031233A (ko) 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
CA2828114A1 (fr) 2010-02-26 2011-09-01 Gary Igor DMITRIENKO Derives de la cephalosporine utiles comme inhibiteurs de la .beta.-lactamase et leurs compositions et procedes d'utilisation
JP5933523B2 (ja) * 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 1−アミノ−2−シクロプロピルエチルボロン酸の誘導体
FR2959061B1 (fr) 2010-04-20 2012-05-11 Commissariat Energie Atomique Substrat fonctionnalise et ses applications
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
WO2012067664A1 (fr) 2010-11-18 2012-05-24 Glaxo Group Limited Composés
EP2487159A1 (fr) 2011-02-11 2012-08-15 MSD Oss B.V. Inhibiteurs du RORgammaT
EP2508506A1 (fr) * 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Préparation d'intermédiaires de la sitagliptine
WO2013033461A1 (fr) * 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Dérivés d'ester d'acide boronique hétérocyclique et leurs utilisations thérapeutiques
WO2013053372A1 (fr) * 2011-10-13 2013-04-18 Therabor Pharmaceuticals Inhibiteurs de type acide boronique de bêta-lactamases
WO2013056163A1 (fr) 2011-10-14 2013-04-18 The Regents Of The University Of California Inhibiteurs de bêta-lactamase
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
US9688702B2 (en) 2011-12-22 2017-06-27 Ares Trading Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
US20150018311A1 (en) * 2012-01-09 2015-01-15 University of Tromsø Therapeutic boron-containing compounds
EP2615080A1 (fr) * 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Préparation d'ingrédients pharmaceutiques actifs de type acide aminés ß purs optiquement et intermédiaires associés
EP2814483A2 (fr) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Méthodes de traitement d'infections bactériennes
WO2013160810A2 (fr) 2012-04-24 2013-10-31 Hetero Research Foundation Nouveaux dérivés d'acide bétulinique à titre d'inhibiteurs du vih
CA2872147A1 (fr) 2012-05-02 2013-11-07 Kansas State University Research Foundation Composes macrocycliques et peptidomimetiques en tant qu'antiviraux a large spectre contre des proteases 3c ou de type 3c de picornavirus, calicivirus et coronavirus
US9156858B2 (en) * 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150014506A (ko) 2012-05-23 2015-02-06 사피라 파르마슈티칼즈 게엠베하 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL2928898T3 (pl) 2012-12-07 2021-10-25 VenatoRx Pharmaceuticals, Inc. Inhibitory beta-laktamaz
KR20150103270A (ko) * 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (fr) 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc Dérivés d'acide boronique et leurs utilisations thérapeutiques
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014232764A1 (en) 2013-03-15 2015-10-08 Zhengyu Long Novel cyclosporin derivatives and uses thereof
EP3140310B1 (fr) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthèse de sels boronate et utilisations de ceux-ci
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016065282A1 (fr) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Formulation nasale, kit nasal, et procédé d'augmentation des taux nasaux d'oxyde nitrique (no)
AU2016252555A1 (en) 2015-04-24 2017-11-09 Melinta Therapeutics, Inc. Methods of treating bacterial infections

Also Published As

Publication number Publication date
CN106536529B (zh) 2019-09-27
JP2017526636A (ja) 2017-09-14
EP3164406C0 (fr) 2024-12-25
KR20170024087A (ko) 2017-03-06
EP3164406B1 (fr) 2024-12-25
ZA201608682B (en) 2019-06-26
US20170136047A1 (en) 2017-05-18
US10206937B2 (en) 2019-02-19
MX2016016666A (es) 2017-08-08
AU2015284307A1 (en) 2017-02-02
CN106536529A (zh) 2017-03-22
EP3164406A1 (fr) 2017-05-10
JP6700203B2 (ja) 2020-05-27
EA201692301A1 (ru) 2017-06-30
EP3164406A4 (fr) 2018-04-04
WO2016003929A1 (fr) 2016-01-07

Similar Documents

Publication Publication Date Title
EP3164406B1 (fr) Dérivés d'acide boronique et leurs utilisations thérapeutiques
US12509475B2 (en) Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) Boronic acid derivatives and therapeutic uses thereof
US10618918B2 (en) Substituted boronic acids as antimicrobials
AU2014204045B2 (en) Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) Boronic acid derivatives and therapeutic uses thereof
JP6672176B2 (ja) ボロン酸誘導体およびその治療的使用
US9241947B2 (en) Boronic acid derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831